The peptide and oligonucleotide CDMO market size is expected to grow from $2.49 billion in 2023 to $7.4 billion in 10 years. Due to the increasing number of chronic disease cases across the globe, the market is expected to exhibit a positive growth rate.
NEWARK, April 22, 2024 (GLOBE NEWSWIRE) — Brainy Insights estimates the global peptide and oligonucleotide CDMO market to grow from USD 2.49 billion in 2023 to USD 7.4 billion by 2033. I am. Peptide and oligonucleotide drugs offer wide flexibility in the treatment of various diseases. , as well as the way they are manufactured and regulated. Creative approaches need to be explored to innovate more complex formulations. Leveraging a peptide and oligonucleotide contract development and manufacturing organization (CDMO) not only provides technical expertise but also allows pharmaceutical companies to focus on key strengths such as research and development, clinical studies, and marketing operations. Increase productivity while reducing internal risks. Manufacturing processes lead to streamlined operations and accelerated timelines during the drug development stage. This includes mitigating the potential associated issues by implementing this strategic outsourcing model approach instead.
Request to download a sample research report – https://www.thebrainyinsights.com/enquiry/sample-request/14184
Report scope details
|
Report scope |
detail |
|
Forecast period |
2024-2033 |
|
base year |
2023 |
|
Market size in 2023 |
$2.49 billion |
|
Market size in 2033 |
7.4 billion USD |
|
CAGR |
11.5% |
|
Number of pages in the report |
237 |
|
Target segment |
Application type |
|
driver |
Increased incidence of chronic diseases |
|
opportunity |
Adopting an outsourcing strategy |
Key insights into the peptide and oligonucleotide CDMO market
Asia Pacific is expected to grow at the highest CAGR during the forecast period.
During the forecast period, Asia Pacific is expected to grow at the highest CAGR among the global peptide and oligonucleotide CDMO market. The Asia-Pacific region will expand significantly. The global peptide and oligonucleotide CDMO market has witnessed Asia-Pacific emerging as a vibrant and rapidly expanding region. Growth in countries such as India, Japan, China, and South Korea is driving this development due to several factors, including large population sizes, stimulating healthcare investment, and emphasis on biopharmaceutical advances. The Asia-Pacific region’s share of the peptide and oligonucleotide contract development and manufacturing organization (CDMO) market has increased significantly in recent years. This aspect is mainly due to the region’s economic prosperity and growth, making it an attractive location for pharmaceutical production outsourcing. Additionally, rising research and development efforts complemented by improvements in healthcare infrastructure have strengthened the region’s market share expansion trend.
The oligonucleotide segment is expected to hold the second largest market share during the forecast period.
Type segments include peptides and oligonucleotides. The oligonucleotide segment is expected to hold the second largest market share during the forecast period. The increasing utilization of gene therapy and the identification of nucleic acid-based interventions as promising therapeutic approaches are driving the growth of oligonucleotide market share. Oligonucleotides are leading the way in tackling rare diseases, genetic conditions, and certain types of cancer. The proliferation of research projects and clinical studies related to oligonucleotide therapeutics accounts for a significant portion of the market presence within the CDMO domain.
The research institute segment is expected to grow at the highest CAGR during the forecast period.
The application segment is divided into pharmaceutical companies, biotechnology companies, research institutions, etc. The research institute segment is expected to grow at the highest CAGR during the forecast period. The contribution of research institutions to scientific discoveries, innovative technologies, and early-stage research has a significant impact on the peptide and oligonucleotide CDMO market share. Research institutions play a key role in uncovering the therapeutic potential of peptides and oligonucleotides, thereby creating opportunities to collaborate with pharmaceutical companies and CDMOs, directly impacting market share. The peptide and oligonucleotide CDMO market is growing through laboratory innovations advancing synthetic methods, analytical techniques, and delivery systems. These breakthroughs are of interest to industry stakeholders as they formulate drug development and manufacturing strategies based on the findings published by these organizations.
For detailed analysis of this report, please visit https://www.thebrainyinsights.com/report/peptide-and-oligoquantity-cdmo-market-14184.
Recent developments:
• In August 2020, Agilent Technologies expanded its state-of-the-art manufacturing facility in Frederick, Colorado, to create “oligos,” small DNA and RNA molecules used to create nucleic acid-based medicines. Then he announced. . The discovery of oligos could lead to the development of new treatments for a variety of diseases, including coronavirus disease (COVID-19), cancer, heart disease, and other rare infections. This expansion increases production capacity for therapeutic oligos at the Frederick location.
Market trend
Driving force: increasing demand for peptide and oligonucleotide therapeutics
The increasing demand for peptide- and oligonucleotide-based therapeutics is the main factor driving the expansion of the CDMO industry. Pharmaceutical companies value peptides and oligonucleotides because they can precisely target specific diseases. As knowledge of their healing potential increases, pharmaceutical companies have begun to incorporate them into their development processes, resulting in a proliferation of specialized CDMO services. This factor is stimulating the market growth and development.
Suppression: Lack of skilled labor
Although technological advances stimulate the industry, integrating emerging technologies can be difficult for certain peptide and oligonucleotide CDMOs. Companies without state-of-the-art technology proficiency or resources may encounter obstacles in adapting to modern synthetic methodologies, analytical approaches, and distribution systems, limiting their competitiveness in a developing context. . This factor restrains the growth and development of the market.
Opportunity: Expanding biopharmaceutical industry
As the biopharmaceutical industry continues to expand, witnessing the rise of biotech companies and superior biological treatment options, demand for CDMO services centered around peptides and oligonucleotides is increasing. These types of companies often have limited production capacity within their facilities. Therefore, specialized CDMOs are required to facilitate both the purification and manufacturing stages of peptide or oligonucleotide drug development. This factor is expected to provide significant growth opportunities in the coming years.
Interested in obtaining a research report? Contact us before purchasing – https://www.thebrainyinsights.com/enquiry/buying-inquiry/14184
Some of the key players operating in the peptide and oligonucleotide CDMO market are:
• Bachem
• Polypeptide group
• Silentis, SA
・STA Pharmaceutical Co., Ltd.
• Creative peptides
• Curia Global Co., Ltd.
• Euro API
• Merck KGaA
• Origene Pharmaceutical Services Co., Ltd.
Main segments covered in the market:
By type:
• Peptide
• Oligonucleotides
By application:
• Pharmaceutical and biotech companies
• research Institute
• others
By region
• North America (USA, Canada, Mexico)
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and other South America)
• Middle East and Africa (UAE, South Africa, rest of MEA)
Have any questions? Ask an expert: https://www.thebrainyinsights.com/enquiry/speak-to-analyst/14184
About the report:
The market is analyzed on the basis of value (USD Billion). All segments are analyzed globally, regionally and by country. The study includes analysis of more than 30 countries in each part. The report analyzes drivers, opportunities, constraints, and challenges to gain key market insights. This research includes Porter’s Five Forces Model, attractiveness analysis, product analysis, supply and demand analysis, competitive position grid analysis, distribution, and marketing channel analysis.
About Brainy Insights:
The Brainy Insights is a market research company that aims to provide actionable insights to improve business acumen for companies through data analysis. We have robust predictive and estimation models to achieve our clients’ goals of achieving high-quality results in a short period of time. We offer both customized (client-specific) and syndicated reports. The repository of syndicated reports is diverse across all categories and subcategories across domains. Our customized solutions are tailored to meet our clients’ requirements, whether they are looking to expand in global markets or planning to launch a new product.
inquiry
Avinash D
Business development manager
Phone: +1-315-215-1633
Email: sales@thebrainyinsights.com
Website: www.thebrainyinsights.com
